Integra LifeSciences Holdings Corp Stock News

Integra LifeSciences (IART) came out with quarterly earnings of $0.76 per share, missing the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.86 per share a year ago.

Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (IART) and Idexx Laboratories (IDXX). But which of these two stocks offers value investors a better b

International expansion and the strong prospects of the CSS segment bode well for Integra (IART).

PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release third quarter 2023 financial re

PRINCETON, N.J., Sept. 01, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that Lea Knight, chief financ

Investors continue to be optimistic about Integra (IART) based on the prospects of its CSS segment and a stable liquidity position.

Integra (IART) reported earnings 30 days ago. What's next for the stock?

In spite of facing foreign exchange fluctuations across its non-U.S. business, Integra (IART) is successfully broadening its international footprint.

Integra LifeSciences Holdings Corporation faces uncertainties and challenges due to the ongoing issues at its Boston manufacturing facility. The company's financials have been impacted by this, despit

In CSS, Integra (IART) registers strong growth owing to high single-digit growth in Advanced Energy and mid-single-digit growth in CSF management during Q2.

Integra LifeSciences (IART) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.82 per share a year ago.

Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street e

Integra's (IART) Codman Bactiseal EVD lowers financial burdens and guarantees a safe clinical outcome in patients with aSAH-related hydrocephalus.

PRINCETON, N.J., July 03, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release second quarter 2023 financial r

Integra (IART) announces the completion of patient enrollment in the DuraSorb IDE clinical study.